Business
Alzheimer’s drug aducanumab faces major setback as US authorities consider whether to approve it – ABC News
A drug company is seeking to get an experimental Alzheimer’s drug approved by the FDA. If they succeed it would be a major breakthrough. But just how convincing…
For almost two decades, the field of Alzheimer’s research has been dogged by treatment failures, leaving patients and their families desperate for hope.
But the makers of a new experimental drug, currently under consideration for regulatory approval by the US Food and Drug Administration (FDA), want to change that.
If Aducanumab, developed by pharmaceutical company Biogen, is approved by the FDA, it would be the first Alzheimer’s drug to be greenlit in 20 years.
Last week, Biogen’s stock price soared…
-
Business17 hours agoCould a small investor today match the historic returns of Warren Buffett?
-
Noosa News15 hours agoQueensland government to set up $400m energy investment fund
-
Business11 hours agoAustralian rare earths companies trading at record levels as China tightens export controls
-
Business9 hours agoWhat’s Macquarie’s price target on Mineral Resources shares?